Recruiting PHASE3 INTERVENTIONAL 5-arm NCT07431281

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Sponsor: AstraZeneca

Conditions Esophageal Cancer Gastric Cancer Gastroesophageal Junction Adenocarcinoma

Interventions 5-Fluorouracil Capecitabine Leucovorin Nivolumab Oxaliplatin Rilvegostomig Sonesitatug vedotin Zolbetuximab

Updated 1 time since 2026 Last updated: Feb 23, 2026 Started: Feb 3, 2026 Primary completion: Aug 16, 2029 Completion: Oct 27, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07431281, this PHASE3 trial focuses on Esophageal Cancer and Gastric Cancer and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, Canada , Ahmedabad, India , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Atlanta, United States , Augsburg, Germany , Bangkok, Thailand , Barcelona, Spain , Barretos, Brazil , Beijing, China and 186 more locations